FDA issues multiple RECALLS of blood pressure and cholesterol drugs over contamination and mislabeling
The Food and Drug Administration (FDA) announced nationwide recalls of blood pressure and cholesterol medications due to contamination with cancer-causing toxins (nitrosamines), mislabeled packaging and cross-contamination with other drugs—highlighting systemic failures in pharmaceutical manufacturing and regulation.
Over 580,000 bottles of prazosin hydrochloride (Minipress/Prazin) were recalled after testing revealed N-nitroso Prazosin, a DNA-damaging nitrosamine linked to cancer in animal studies. The FDA classified it as serious but stopped short of declaring an emergency.
Unichem Pharmaceuticals recalled 60,000 doxazosin tablets for misprinted labels, raising concerns about quality control at its India facility (previously flagged by the FDA). Glenmark Pharmaceuticals recalled 11,136 bottles of a blood pressure drug contaminated with traces of a cholesterol medication (ezetimibe).
Critics accuse the FDA of downplaying risks through voluntary recalls and Class III classifications, while evidence mounts of unsanitary conditions (e.g., rodent infestations) at drug facilities and delayed public warnings. Foreign manufacturing dominance and FDA-Big Pharma ties further erode trust.
Patients are urged to check recalled lot numbers, consult doctors before stopping medication, report adverse effects to the FDA’s MedWatch and stay vigilant. Recalls are increasingly common due to lax oversight and corporate prioritization of profits over safety.
Read Full Article: https://www.naturalnews.com/2026-02-21-fda-recalls-blood-pressure-and-cholesterol-drugs.html
